Latest Breaking News On - Edwardm kaye - Page 2 : comparemela.com

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

– Data anticipated in Q1 2024 from studies of STK-001 for the treatment of Dravet syndrome – – End of Phase 1/2a study results and OLE data from patients receiving ongoing treatment; Analyses.

United statesUnited kingdomEdwardm kayeEdward kayeExchange commissionAmerican epilepsy societyCompany annual report on formAugmentation of nuclear gene outputAcadia pharmaceuticalsStoke therapeutics incStoke therapeuticsChief executive officerAutosomal dominant optic atrophyHealthcare conferenceTargeted augmentationNuclear gene output

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

– STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing.

United statesUnited kingdomEdwardm kayeInternational epilepsy congressCompany annual report on formAugmentation of nuclear gene output is stokeExchange commissionAmerican epilepsy societyStoke therapeutics incAcadia pharmaceuticalsAugmentation of nuclear gene outputStoke therapeuticsChief executive officerDominant optic atrophyYear to date financialCollaboration agreement

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases –BEDFORD, Mass. (BUSINESS WIRE) Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote.

United statesUnited kingdomIan smithEdwardm kayeIanf smithEric rojasManchester metropolitan university united kingdomAlkeus pharmaceuticalsAugmentation of nuclear gene outputSenior advisor to bain capital life sciencesVexsol incStoke therapeutics incViacyte incVertex pharmaceuticalsStoke therapeuticsChief executive officer

Stoke Therapeutics (STOK) Appoints Ian Smith to its Board

Stoke Therapeutics (STOK) Appoints Ian Smith to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ianf smithEdwardm kayeIan smithVertex pharmaceuticalsAlkeus pharmaceuticalsVexsol incSenior advisor to bain capital life sciencesManchester metropolitan university united kingdomStoke therapeutics incViacyte incStoke therapeuticsChief executive officerSenior advisorBain capital life sciencesExecutive chairSolid biosciences

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – .

United statesUnited kingdomEdwardm kayeIan smithIanf smithViacyte incStoke therapeutics incManchester metropolitan university united kingdomAugmentation of nuclear gene outputSenior advisor to bain capital life sciencesVexsol incAlkeus pharmaceuticalsVertex pharmaceuticalsStoke therapeuticsChief executive officerSenior advisor